50BA Stock Overview
A clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Bicycle Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.50 |
| 52 Week High | US$26.00 |
| 52 Week Low | US$10.70 |
| Beta | 0.93 |
| 1 Month Change | -11.54% |
| 3 Month Change | -41.92% |
| 1 Year Change | -31.14% |
| 3 Year Change | -69.74% |
| 5 Year Change | n/a |
| Change since IPO | -50.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 50BA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.5% | -3.2% | 2.7% |
| 1Y | -31.1% | -7.9% | 17.0% |
Return vs Industry: 50BA underperformed the German Biotechs industry which returned -7.9% over the past year.
Return vs Market: 50BA underperformed the German Market which returned 17% over the past year.
Price Volatility
| 50BA volatility | |
|---|---|
| 50BA Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 50BA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 50BA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 284 | Kevin Lee | www.bicycletherapeutics.com |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
Bicycle Therapeutics plc Fundamentals Summary
| 50BA fundamental statistics | |
|---|---|
| Market cap | €825.80m |
| Earnings (TTM) | -€158.46m |
| Revenue (TTM) | €35.16m |
23.5x
P/S Ratio-5.2x
P/E RatioIs 50BA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 50BA income statement (TTM) | |
|---|---|
| Revenue | US$36.90m |
| Cost of Revenue | US$168.05m |
| Gross Profit | -US$131.15m |
| Other Expenses | US$35.12m |
| Earnings | -US$166.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | -355.45% |
| Net Profit Margin | -450.64% |
| Debt/Equity Ratio | 0% |
How did 50BA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 02:23 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bicycle Therapeutics plc is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Kalpit Patel | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |